Ibonatide, a new diabetes drug of Changshan pharmaceutical industry, is expected to obtain clinical approval in the second half of the year

Changshan pharmaceutical industry said in a conference call that the company's first class 1 new drug, ibuprofen, is expected to obtain the first phase of clinical trial approval and start clinical trials in the second half of this year At the end of last year, the product was applied for phase 1 clinical application and accepted Ibn is an intestinal hypoglycemic analog developed by Changshan kaijiejian, a joint venture of Changshan pharmaceutical and conguchem LLC in 2012, for the treatment of type 2 diabetes At present, the product has completed phase I and phase II clinical trials in the United States and Canada According to the research data, ibn-a-peptide has the advantages of long half-life, good clinical tolerance, once a week administration and definite effect Ibn is an important strategy for Changshan pharmaceutical industry to diversify its products If it can be successfully developed, it will reduce the risk of the company's excessive dependence on heparin products Changshan Pharmaceutical Co., Ltd is mainly engaged in heparin series products There are only two kinds of heparin preparations: low molecular weight heparin calcium injection and heparin sodium injection The company's performance is easily affected by the price fluctuation of API and preparation products In addition to a variety of heparin products and ibuprofen, the company's new products under research include a long-acting insulin drug, an antithrombotic drug and two anticancer drugs, "the anticancer drug is commissioned to be developed by a domestic university, and the technology belongs to the company itself," the person said